NEW YORK, November 29, 2016 /PRNewswire/ --
For today, Stock-Callers.com reviews the following equities in the MedicalLaboratories and Research space: Thermo Fisher Scientific Inc. (NYSE: TMO), Bruker Corp. (NASDAQ: BRKR), VWR Corp. (NASDAQ: VWR), and Laboratory Corp. of America Holdings (NYSE: LH). These companies are part of the Healthcare sector which was mostly
Thermo Fisher Scientific
On Monday, shares in Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc. recorded a trading volume of 3.63 million shares, which was above their three months average volume of 1.79 million shares. The stock ended the session 2.68% lower at $140.32. The Company's shares are trading 5.30% below their 200-day moving average. Moreover, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide, have a Relative Strength Index (RSI) of 31.19.
On November 10th, 2016, Thermo Fisher's board of directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 16th, 2017, to shareholders of record as of December 15th, 2016.
On November 10th, 2016, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock. Your complete research report on TMO can be retrieved for free at:
Billerica, Massachusetts headquartered Bruker Corp.'s stock closed the day 0.48% lower at $22.85 and with a total trading volume of 520,382 shares. The Company's shares have advanced 13.74% in the past month and 1.20% in the previous three months. The stock is trading 4.06% above its 50-day moving average. Additionally, shares of Bruker, which together with its subsidiaries, designs and manufactures scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 57.37.
On November 10th, 2016, research firm Leerink Partners resumed its 'Market Perform' rating on the Company's stock.
On November 22nd, 2016, Bruker announced that it has completed the acquisition of the preclinical PET imaging business of Oncovision, a leading provider of innovative medical imaging devices. Bruker had previously announced an agreement to acquire this business in September 2016. Financial terms were not disclosed. BRKR free report is just a click away at:
Shares in Radnor, Pennsylvania-based VWR Corp. recorded a trading volume of 1.83 million shares, which was higher than their three months average volume of 686,320 shares. The stock ended yesterday's trading session 2.93% lower at $26.21. The Company's shares are trading below their 50-day moving average by 4.34%. Furthermore, shares of VWR Corp., which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have an RSI of 40.40.
On November 03rd, 2016, VWR Corp. announced the acquisition of two companies, Reliable Biopharmaceutical and BioArra. Reliable Biopharmaceutical, a manufacturer of high quality active pharmaceutical ingredients (APIs) and high purity ingredients (HPIs) such as cGMP excipients and advanced intermediates for the biopharmaceutical industry, enhances VWR's growing custom chemical and biochemical manufacturing portfolio. Reliable Biopharmaceutical offers highly-flexible, scalable and solution oriented production ranging from small batch clinical manufacturing to full scale commercial production. BioArra is a leading producer of U.S. origin serum-based products for use in research and production. Founded in 2008 and headquartered in Eagleville, Pennsylvania BioArra produces semi-processed serum from various USDA approved supplier locations. The company did not disclose the financial details of the transaction.
On November 04th, 2016, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Buy' to 'Neutral'. Sign up for your complimentary research report on VWR at:
Laboratory Corp. of America
Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' stock finished Monday's session 1.41% lower at $125.71 with a total trading volume of 722,735 shares. The Company's shares have advanced 1.42% in the last one month and 1.67% since the start of this year. The stock is trading below its 200-day moving average by 1.70%. Additionally, shares of Laboratory Corp. of America, which operates as an independent clinical laboratory company worldwide, have an RSI of 45.18.
On November 21st, 2016, Laboratory Corp. announced that IDG's Computerworld recently recognized Dimitris Agrafiotis, Ph.D., chief data officer and head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. Covance is the drug development business of Laboratory Corp. Register for free on Stock-Callers.com and download the latest research report on LH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Do fad diets really work? Here are some disadvantages and side-effects of going on a fad diet. ...
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...View All